beigene.com (BGNE): Operating Profitability

Public company logo of BeiGene Ltd (BGNE)

State-of-the-art plants in China and New Jersey ensure the stability of BeiGene, Ltd. (BGNE). This operating margin chart visualizes cost management efficiency, where 17.80 represents the current metric level. Successful tests of new drugs allow the company to capture market share without resorting to dumping. However, trade wars between the US and China create risks of isolating the business from Western investments and sales.

BGNE: BeiGene Ltd. Operating Return on Sales 07/04/2022 - 11/20/2026

Comprehensive metric breakdowns and analytics for BeiGene (BGNE)

- share price and consensus valuation forecast:
- stock exchange capitalization data:
Fundamental valuation:BeiGene, Ltd., BGNE
Core merchandise of beigene.com

BeiGene, Ltd. (BGNE) expansion in the oncology sector and its dominance driven by unique drugs allow the company to avoid dumping, directly impacting the efficiency of its business model. An analysis of operating profitability reflects the portion of revenue remaining after covering operating expenses before taxes and interest, which characterizes the asset's fundamental ability to generate profit and determines its investment grade.

Competing companies

Operating Profitability BeiGene Ltd|Halozyme Therapeutics - Operating Profit Margin|Operating Sales Margin RVMD (Revolution Medicines Corp)|Operating Profit Ratio AAPG|Operating Profitability CG Oncology Therapeutics CGON|Operating Profit Rate URGN|BCAX: Operating Sales Margin|PSNL: Operating Profitability|Erasca (ERAS) - Operating Profitability|DCTH - Profitability of Operations|YMAB (Y-mAbs Corp) - Operating Margin|Operating Sales Margin Aura Biosciences (AURA)|Operating Profitability Candel Therapeutics Inc. (CADL)|Operating Sales Margin Accuray, Inc. ARAY|Operating Profitability sellaslifesciences.com SLS|Operating Profit Rate ACTU|CTOR - Operating Profitability|Profitability of Operations tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Operating Profitability|FATE: Operating Profit Ratio|WHWK (Aadi Bioscience, Inc.) - Operating Margin|TCRX (TScan Therapeutics) - Operating Profit Ratio|Operating Profitability Champions Oncology (CSBR)|Profitability of Operations XBiotech USA|Operating Profitability CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Operating Return on Sales|RADX - Operating Profitability|ARTV - Operating Margin|Adlai Nortye Ltd (ANL) - Operating Profitability|Veru Pharma - Operating Profit Rate|Operating Profitability Tempest Therapeutics Corp|Return on Sales by Operating Profit XLO (Xilio Therapeutics, Inc.)|Operating Margin RENB|MURA (Mural Oncology) - Operating Profit Rate|Operating Margin KAPA (Kairos Pharma Ltd)|OKUR: Return on Sales by Operating Profit|GDTC: Operating Sales Margin|CRIS - Operating Margin|APLM: Operating Margin|Operating Return on Sales tharimmune.com (THAR)|ADVB (Advanced Biomed Corp) - Operating Margin|Operating Margin Genprex Inc.|Operating Margin CLDI|Operating Sales Margin Sunshine Biopharma, Inc. SBFM|Operating Margin XBIO (Xenetic Biosciences)|Operating Profit Rate SLRX|PPBT - Operating Profitability|AONC (aoncology.com) - Return on Sales by Operating Profit|CKPT: Operating Margin|Elevation Oncology - Operating Profit Rate|ICAD (iCAD) - Operating Margin|IKNA: Operating Profit Rate|Operating Profitability Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operating Profit Rate|Operating Profitability MorphoSys Corporation MOR|NAYA: Return on Sales by Operating Profit|Ascentage Pharma Group International - Operating Margin